Acute Myeloid Leukemia (non-APL) · line 1 · Oral azacitidine (CC-486 / Onureg) maintenance — AML CR1, transplant-ineligible (QUAZAR AML-001)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-ORAL-AZA-QUAZAR-MAINTENANCE |
| ID | IND-AML-CR1-ORAL-AZA-MAINTENANCE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-AML |
| Sources | SRC-ELN-AML-2022 SRC-NCCN-AML-2025 SRC-QUAZAR-WEI-2020 |
Notes
STUB — pending Clinical Co-Lead signoff. Standard-track post-induction maintenance for AML CR1 in transplant-ineligible patients. line_of_therapy: 1 reflects continuation of the 1L pathway (analogous to MM lenalidomide maintenance pattern). Engine should activate after induction → CR/CRi → no-HCT decision branch. Ukraine access barrier dominant (Onureg not registered); engine must flag funding pathway.
Used By
No reverse references found in the YAML corpus.